NCT04797481

Brief Summary

The inability of the heart to pump out blood to the rest of the body organs is called heart failure (HF). HF affects almost 920,000 people in the UK, costing the NHS up to £2.33bn/year. Physical exercise programmes aiming to improve the heart's ability to pump out blood are used to a) reduce the risk of life-threatening events (e.g., heart attack), b) reduce admissions to hospital and c) improve individual's physical independence (e.g., walking unsupported, being able toperform daily essential activities). However, these physical exercise programmes have been cut short under the current COVID-19 pandemic, with support in most UK regions being restricted to online videos and advice. With many people with HF being asked to be "shielded" or "self-isolate" for an unknown duration, it is important to develop a reliable and cost-effective physical exercise service to support this clinical group. The research team has developed a novel physical exercise programme, fully-delivered online. Before assessing if it could improve clinical outcomes (e.g., heart's ability to pump out blood) and how cost-effective it could be, a 10-month pilot study is proposed that will assess if the proposed online physical exercise programme could be performed in people with HF. Thirty participants will be allocated at random into two groups: Group A will receive up to 24 exercise sessions and up-to 3 lifestyle workshops, in addition to usual care over a 2-month period. Group B will receive a self-care exercise programme (≥3 sessions per week) for a two-month period in addition to usual care. Prior to the group random allocation, online assessments will be performed including demographics and clinical history, the ability to perform daily activities, sedentary or physical activity habits and quality of life. The assessments including interviews to assess participant's experiences will be repeated at 2 months

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable heart-failure

Timeline
Completed

Started Jun 2022

Typical duration for not_applicable heart-failure

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 4, 2021

Completed
11 days until next milestone

First Posted

Study publicly available on registry

March 15, 2021

Completed
1.2 years until next milestone

Study Start

First participant enrolled

June 1, 2022

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2025

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2025

Completed
Last Updated

October 15, 2024

Status Verified

October 1, 2024

Enrollment Period

2.7 years

First QC Date

March 4, 2021

Last Update Submit

October 10, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Adherence

    Number of sessions completed.

    2 months

  • Acceptability of procedures.

    Acceptability of procedures will be assessed by examining reasons for drop-out in discontinuing participants and comparing attrition between groups

    2 months

  • Recruitment rates.

    Recruitment rates will be measured as rate of invited participants who are eligible and consenting

    2 months.

Secondary Outcomes (12)

  • 30-second chair-stand test

    Baseline.

  • 30-second chair-stand test

    2 months

  • Step in place test

    Baseline

  • Step in place test

    2 months

  • arm curl test

    baseline

  • +7 more secondary outcomes

Study Arms (2)

Novel Intervention

EXPERIMENTAL

Novel Intervention Exercise group.

Procedure: Exercise

Control

ACTIVE COMPARATOR

Self-managed Exercise group.

Procedure: Self-managed exercise

Interventions

ExercisePROCEDURE

Group A participants will be invited to attend up to 24 exercise sessions (2 sessions per week and a 3rd optional) and 2 virtual (online; a 3rd will be optional) HF workshops over 8 weeks. All sessions will be delivered via online platforms, with 1 facilitator supporting up to 8 participants simultaneously in each session.

Novel Intervention

Group B participants will be provided with a self-care exercise programme. The exercise programme will be home-based with a mixture of online video calls and telephone support contacts, alternating once every other week. The video or telephone contacts will be mutually agreed by the patient and the facilitator at a mutually convenient time and will aim to support Group B participants, by offering advice and tracking progress. Patients will be provided with two exercise programmes: I) a chair-based exercise programme (DVD will be provided), and ii) a progressive walking training programme (a manual will be provided). Patients will be advised to exercise ≥3 times per week, starting from their own personal level and gradually building up over 8 weeks in session's duration, frequency of sessions per week, and walking pace.

Control

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \> 18 yrs. of either gender
  • Confirmed diagnosis (by echocardiography) of HF reduced left ventricular ejection fraction
  • Sinus rhythm N-Terminal pro-Brain Natriuretic Peptide (NTproBNP) is \>400 ng/L at the time of referral to the diagnostic clinic if in sinus rhythm.
  • Ability to exercise

You may not qualify if:

  • Non-ambulant status
  • Current pregnancy
  • Scheduled major cardiac surgery
  • The presence of an ICD or CRT-D device
  • Severe pulmonary hypertension defined as systolic PAP of \>60 mmHg
  • NYHA function class IV
  • Lack of internet connection
  • Inability/unwillingness to give informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sheffield Hallam University

Sheffield, Yorkshire, S10 2BP, United Kingdom

Location

MeSH Terms

Conditions

Heart Failure

Interventions

Exercise

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Markos Klonizakis, D.Phil

    Sheffield Hallam University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 4, 2021

First Posted

March 15, 2021

Study Start

June 1, 2022

Primary Completion

February 28, 2025

Study Completion

July 30, 2025

Last Updated

October 15, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations